Tonix Pharmaceuticals Holding Corp.
TNXP · XNASCIK 1430306fmd_02PQCZ97VDV2HFJRKP45QG5ES9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 69 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | 8 | 10 | 13 |
| Net interest income | – | – | – | – | – | – | – | – | – | – |
| Cost of revenue | – | – | – | – | – | – | – | 5 | 8 | 7 |
| Gross profit | – | – | – | – | – | – | – | 3 | 2 | 6 |
| Provision for credit losses | – | – | – | – | – | – | – | – | – | 0 |
| Research and development | 29 | 13 | 18 | 18 | 36 | 69 | 82 | 87 | 40 | 44 |
| Selling, general and administrative | – | – | – | – | – | – | 30 | 35 | 40 | 88 |
| Total operating expenses | – | – | – | – | – | – | – | – | – | – |
| Operating income | (39) | (21) | (26) | (29) | (51) | (92) | (112) | (118) | (137) | (126) |
| Interest expense | – | – | – | – | – | – | – | – | 1 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 4 |
| Other non-operating income (expense) | – | – | – | – | – | – | – | 2 | (1) | (3) |
| Income before taxes | (39) | (21) | (26) | (29) | (50) | (92) | (110) | (117) | (130) | (124) |
| Net income | (39) | (21) | (26) | (29) | (50) | (92) | (110) | (117) | (130) | (124) |
| Net income to common shareholders | – | (21) | (29) | (31) | (52) | (92) | (117) | (117) | (130) | (124) |